TriSalus Reports Q3 2024 Financial Results and Provides Business Update
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year– Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025– Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system’s full access to the $375 million embolization market– Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system’s reach into the $400 million thyroid embolization market– Presented positive Phase 1 data from PERIO-01 trial in patients with uveal melanoma with liver metastases (UM-LM) at the Society for Immunotherapy of Cancer (SITC) meeting and announced the strategic decision to seek a partner to drive further development of this indication– Hosting earnings call on November 14, 2024 at 9:00 a.m. EST DE
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.MarketBeat
- TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- TriSalus Reports Q3 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences, Inc. (NASDAQ: TLSI) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
TLSI
Earnings
- 11/14/24 - Beat
TLSI
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- TLSI's page on the SEC website